logo-loader
Arecor

Arecor doses first patient in Phase I trial of AT247 diabetes treatment

The firm said the double-blind, three-way cross over study in Austria will compare the results of AT247 against current insulin treatments for people living with Type 1 diabetes

Insulin bottle
AT247 is designed to accelerate the absorption of insulin following injections

Arecor Limited has dosed the first patient in a trial of its ultra-rapid acting insulin product, AT247.

The pharmaceutical firm said the double-blind, three-way cross over study in Austria will compare the results of AT247 against current insulin treatments for people living with Type 1 diabetes.

READ: Arecor given green light to begin Phase I trial of AT247 diabetes treatment

AT247 is designed to accelerate the absorption of insulin following injections, which the company says will enable diabetes patients to more effectively manage their blood glucose levels, particularly after meals.

Sarah Howell, Arecor’s chief executive, said the initiation of the trial was “an important step” in the company’s strategy to develop fast-acting insulins to improve treatments for diabetes.

“I look forward to reporting on the progress of this product candidate, the first in our proprietary product development pipeline.”

--Adds video--

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arecor doses first patient in Phase I trial for ultra-rapid acting insulin...

Dr Sarah Howell, chief executive of Arecor, speaks to Proactive London after announcing the dosing of the first patient in a Phase I clinical trial for its ultra-rapid acting insulin product candidate AT247. AT247 is an ultra-rapid acting product candidate targeting improved treatment for...

on 7/5/19

2 min read